Abstract 1133
Background
Immune checkpoint inhibitors are an important therapy. However, their essence is nonspecific and efficiency of single usage is not satisfactory. The mutant neoantigen specific T (Nas-T) cell, as an adoptive cell treatment, is a specific immunotherapy for each individual. Our previous research has proved that the combined immunotherapy of mutant Nas-T cell and PD1 antibody is more effective than PD1 alone in prolonging PFS (World Conference on Lung Cancer 2018). We aim to evaluate the characteristics of the immune repertoire (IR) as a predictive biomarker for immunotherapy and to construct personalized and specific TCR-T.
Methods
14 patients with advanced solid tumors who failed after multiline treatments were recruited. They were divided into durable clinical benefit (complete response, partial response or stable disease for more than 3 months) and non-durable clinical benefit (DCB and NCB) based on PFS. Peripheral blood was collected at baseline and each cycle. IR-seq of the CDR3 regions of human TCRβ chains was used to interrogate the TCRs frequency. We used single neoantigen to stimulate the infused T cells and performed RNAseq for the sorted CD137(+) cells to obtain the full-length TCR α and β chain. Lastly, we constructed TCR-T cells via transfecting the TCR α/β pair into the T cells of patients and co-cultured with neoantigen to analyze the functionality of TCRs.
Results
After neoantigen pulsing, the clonality of infused T cells pool significantly increased (P = 0.0001), suggesting some tumor-specific T-cells were expanded and enriched after neoantigen pulsing. Compared to baseline, T-cell repertoire of NCB and DCB after 1st cycle displayed significant changes: Shannon 1.19 vs 0.97 (P = 0.002); clonality 0.68 vs 1.19 (P = 0.001). Elevated clonality may indicate expanded tumor-specific T-cells which could recognize mutant neoantigen specifically. Besides, based on the in vitro TCR-T experiments, the constructed TCR-T cells can specifically recognize the mutant neoantigen and lyse the target cells expressing the corresponding neoantigen.Table:
1228P
Neoantigen Sequence | HLA-I typing | TCR Vα | TCR Vβ | |||
---|---|---|---|---|---|---|
Gene name | Sequence* | All V Hits With Score# | Clonal Sequence# | All V Hits With Score# | Clonal Sequence# | |
MTAP/SPINK1 Fused Gene | VLLPRHMKV | A0201 | TRAV35 (574.6) | TGTGCTGGGTATGGCTCTAGCAA CACAGGCAAACTAATCTTT | TRBV19 (646.8) | TGTGCCAGTCGGACAGGGGGA TCACCCCTCCACTTT |
FER | NYVSNVSKF | A2301 | TRAV29DV5 (667.6) | TGTGCAGCTTCAACTGGGGCAAA CAACCTCTTCTTT | TRBV7-2 (626.7) | TGTGCCAGCACCTCTGCCCCC TCCTACGAGCAGTACTTC |
SPINK1 | FLLSALALL | B4403 | TRAV20 (589.1) | TGTGCTGTTCCCCTGGGAACAGG CTTTCAGAAACTTGTATTT (response to neoantigen) | TRBV21-1 (557.8) | TGTGCCAGCAGCAAAGACCCT AGCGGGAATCAAGAGACCCAGTACTTC |
CLCN6 | ALIGAAASL | B6701 | TRAV19 (612.4) | TGTGCTCTTCTGAATTATGGTGGTGC TACAAACAAGCTCATCTTT | TRBV6-5 (675.4) | TGTGCCAGCAGTGGGACAGCCAATGA GCAGTTCTTC (response to neoantigen) |
MTAP | AESFMFRTW | C0401 | TRAV38-2DV8 (658.4) | TGTGCTTATTGGGAGCTTGTCTCTGGGG CTGGGAGTTACCAACTCACTTTC | TRBV5-1 (637.6) | TGCGCCAGCAGCTTGACTAGCGGGGGG TTCTACGAGCAGTACTTC |
TAP1 | RLSLFLALV | C0702 | TRAV16 (622.2) | TGTGCTCCCTGGGCCCTAGGAGGAGG TGCTGACGGACTCACCTTT | TRBV30 (403.4) | TGTGCCTGGAGTGTAACAGGGGGC AAAGCAGATACGCAGTATTTT |
MAN2C1 | FLQGRNFFL |
Conclusions
The mutant Nas-T cell is a personalized immunotherapy. IR is a potential predictive biomarker.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shunchang Jiao.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract